The Medicines Co.
www.themedicinescompany.com
Latest From The Medicines Co.
AZ, Novartis, Roche Take Part In UK’s Big Data Push
Seven hubs will bring together data sets and help accelerate clinical trials.
Vascepa Included In European Dyslipidemia Guidelines Ahead Of Approval
Amarin won't seek approval in the EU until later this year, but doctors there are encouraged to consider Vascepa for patients with high triglycerides despite statin therapy. Also, PCSK9 inhibitor guidelines were solidified for very high risk patients.
Inclisiran’s Safety Data Suggest Game-Changing Potential In PCSK9 Market
The Medicines Co. unveiled Phase III safety data for inclisiran showing safety and tolerability comparable to placebo and efficacy in line with the PCSK9 inhibitor class – which should be the reassurance it needs for the oral agent.
What Else Analysts Want To Know About Phase III Data For TMC’s Inclisiran
Looking to be a game-changer with a highly effective LDL-C-lowering agent dosed twice annually, The Medicines Company says inclisiran met efficacy endpoints in a large Phase III study. But observers await fuller data, including safety details.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Cardiovascular
- Infectious & Viral Diseases
- Inflammation
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- The Medicines Co.
- Senior Management
-
Mark Timney, CEO
Chris Visioli, CFO
Diane Sullivan, Chief Commercial Officer
Peter Wijngaard, PhD, Chief Dev. Officer - Contact Info
-
The Medicines Co.
Phone: (973) 290-6000
8 Sylvan Way
Parsippany, NJ 07054
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice